Empowering Drug Research

Executive Summary JAK2 is a disease target implicated in cancer, immune disorders, and chronic inflammation We used Crucible to generate 50 optimized drug leads on a desktop computer 68% of leads tested (34 out of 50) bind to the disease target, JAK2, as well as, or better than on the market drugs, such as abrocitinib What is JAK2? JAK2 (Janus kinase 2) is a cytokine and growth-factor signaling protein that controls hematopoiesis, immune function, and inflammation.

The adrenergic receptor beta-1 (β1-AR) (Figure 1) is a G protein-coupled receptor primarily expressed in cardiac tissue, where it regulates heart rate, contractility, and conduction velocity in response to catecholamines like epinephrine and norepinephrine. Dysregulation of β1-AR signaling is implicated in a range of cardiovascular diseases, including hypertension, arrhythmias, and heart failure, making it a key therapeutic target. Nearly all existing β1-AR modulators—such as

The dopamine receptor D2 (D2) is a central regulator of dopaminergic signaling in brain regions tied to mood, reward, and cognition, making it an outstanding target for drug development in psychiatric disorders. Dysregulation of D2 has been implicated in conditions such as depression, schizophrenia, bipolar disorder, ADHD, and addiction. In major depressive disorder, altered D2 function is linked to anhedonia and motivational deficits that are poorly addressed by traditional